Nosocomial meningitis due to gram-negative organisms is a difficult clinical problem to manage because of both antibiotic resistance and poor penetration of many antimicrobials across the blood-brain barrier. Ciprofloxacin has potential in treating this condition when used in high doses. We investigated the plasma and cerebrospinal fluid (CSF) levels of ciprofloxacin in a patient with Pseudomonas aeruginosa meningitis who was treated with 400 mg of intravenous ciprofloxacin every 8 hours. Ciprofloxacin levels in plasma peaked at 10.29 mg/L without resulting in accumulation (8-hour trough levels, !1 mg/L), whereas the CSF level increased to 0.9 mg/L. This CSF level was confirmed to be similar 1 week later. After 1 week of therapy, during which there were no side effects attributable to ciprofloxacin, the organism was eradicated, and there was some clinical improvement. We recommend that 400 mg of intravenous ciprofloxacin every 8 hours be considered for treatment of difficult-to-treat gram-negative bacillary meningitis.
studies were performed with use of the initial registration dosage, 200 mg q12h [4, 5, 7, 10, 11] . These and other studies did, nevertheless, uniformly demonstrate penetration of ciprofloxacin into CSF, more so in the presence of inflamed meninges than noninflamed meninges [4, 5, 7, [10] [11] [12] . One clinical study reported a good outcome when much higher doses of ciprofloxacin were used [9] .
For intravenous use, particularly in infections where MICs for organisms may be high or penetration into the site of infection is limited, it would seem that the intravenous use of 400 mg q8h might be a better dosing option [13] [14] [15] . We surmised that this more recently advocated higher dose of intravenous ciprofloxacin would result in higher ciprofloxacin levels in CSF. We studied plasma and CSF pharmacokinetics of ciprofloxacin in a critically ill patient with P. aeruginosa meningitis who was treated with 400 mg of intravenous ciprofloxacin q8h, to document the potential advantage of this dosage regimen.
Materials and Methods

Patient history.
A 68-year-old woman who had undergone diskectomy and laminectomy developed P. aeruginosa meningitis postoperatively; she was treated for 4 weeks with intravenous ceftazidime and gentamicin, to which the organism was susceptible (no MICs were available for the original isolate). She presented again several weeks later with CT evidence of hydrocephalus, together with relapsed P. aeruginosa meningitis. Subsequently, the Etest (AB BIOD-ISK, Solana, Sweden) revealed that the ciprofloxacin MIC for the organism was 0.094 mg/L. Her condition deteriorated rapidly, and she required intubation and ventilation. In view of dilated ventricles, an intraventricular drainage catheter was inserted, and she was treated with 2 g of intravenous ceftazidime q8h, together with gentamicin (day 1). Her clinical state did not improve, and 48 h later (day 3), 400 mg of intravenous ciprofloxacin q8h was added to her therapy, and gentamicin administration was discontinued. Plasma samples. Ciprofloxacin was administered through a dedicated iv catheter via a peristaltic pump 11 h; the first dose was given at 8:00 PM After informed consent was obtained from her next of kin, a 10-mL arterial blood sample was obtained on day 4, 5 h after the start of the second dose of ciprofloxacin; these blood samples were then obtained hourly until 2 h after the start the third dose of ciprofloxacin (table 1) . Further plasma samples were obtained on day 11 and a trough as well was obtained on day 12.
CSF samples. A 5-mL CSF sample for ciprofloxacin analysis was drained from the intraventricular catheter at 9:00 AM on day 4, and then these samples were obtained hourly until the catheter was removed that day (table 1) . A further CSF specimen was obtained when lumbar puncture was performed on day 11. CSF samples were obtained from 3 noninfected patients (control patients) who had intraventricular drains in situ because of raised intracranial pressure; these controls were not receiving ciprofloxacin treatment. Informed consent for CSF sampling and analysis was obtained from their next of kin.
HPLC. Ciprofloxacin levels in plasma and CSF were measured by HPLC according to the method of Joos et al. [16] ; this method was adapted for the resources of our laboratory and for application to CSF. The inclusion of lomefloxacin hydrochloride as an internal standard was necessary to compensate for different protein levels in CSF samples from controls, CSF samples from patients with inflamed meninges, and plasma samples.
Results
Clinical findings.
Results of sequential CSF examinations are presented in table 2. Our patient continued to have marked pleocytosis and elevated protein levels that suggested ongoing inflammation of the meninges with presumed compromise of the blood-brain barrier.
Although all the signs of infection in the patient abated, the patient remained in a severely disabled state and was transferred to a hospital nearer to her home for ongoing care. MRI revealed multifocal areas of cerebral ischemia. She completed 6 weeks of intravenous ceftazidime treatment, and oral ciprofloxacin therapy was continued for long-term suppression. It was believed that necrosis from cerebral vasculitis as a consequence of meningitis was largely the cause of the poor outcome.
Ciprofloxacin levels. The peak plasma level of ciprofloxacin (table 1) was higher than previously found with a dosage of 400 mg q8h [15] . Nonetheless, there was no accumulation even after 1 week of treatment with 1200 mg/d, since the trough level on day 12 was lower than that on day 4. Curiously, ciprofloxacin penetration into CSF seemed to increase until 15 h after initiation of therapy. The CSF level then appeared to remain constant.
Discussion
To our knowledge, this is the first report of CSF ciprofloxacin levels associated with the use of a dosage regimen of 400 mg of intravenous ciprofloxacin q8h. There have been few other studies in which this dose was used. Fink et al. [14] , in a clinical study of severe pneumonia, reported good results, and we [15] previously documented plasma levels associated with this dosage regimen. Both studies showed a low side-effect profile, the former study documenting a 1% seizure rate and the latter showing no side effects attributable to ciprofloxacin and no accumulation in patients with normal renal function. This dose would therefore seem to be the preferred dose for eradication of organisms for which the MICs are higher or where penetration of the agent is limited.
As for many other antibiotics, the optimal intravenous dose of ciprofloxacin is unknown [2] . We have previously shown that dosages of 400 mg of ciprofloxacin q8h can yield a peak level 18 times the MIC and an AUC of 1100 for organisms for which MICs are !0.5 mg/L [15] . These data also demonstrated that the ciprofloxacin level was maintained above this MIC for most of the dosing period.
The peak plasma level in this patient was 10.29 mg/L, slightly higher than levels reported elsewhere [15] . Combining the plasma ciprofloxacin levels from the two dosing intervals (table  1) , we estimated an AUC 8h of almost 22 mg.h/L, also higher than reported elsewhere [15] .
This patient had raised intracranial pressure necessitating intraventricular drainage for clinical reasons, allowing us to obtain a number of timed CSF samples. To our knowledge, this is the first clinical study of CSF ciprofloxacin levels with such frequent sampling. We were able to demonstrate relatively constant CSF levels in the presence of peak and trough plasma levels. The CSF ciprofloxacin levels we found gave a high concentration:MIC ratio and were maintained for a prolonged time above the MIC. Under the assumption of a constant CSF level of 0.9 mg/L, this finding extrapolates to a CSF AUC 24h of 22 mg.h/L. We have no reference level with which to compare this finding; however, assuming that this higher intravenous dose would achieve higher levels than those documented elsewhere in CSF (with the exception of the findings of Wong-Beringer et al. [9] ), we can surmise only that this level is adequate for the killing characteristics of ciprofloxacin in CSF. Lower intravenous doses of ciprofloxacin may produce a lower CSF AUC that may, in turn, fail to eradicate resistant organisms (something that Wong-Beringer et al. [9] found when treating meningitis due to multidrug-resistant P. aeruginosa). Wong-Beringer et al. [9] started off with a dosage of 400 mg q12h and, in view of a lack of clinical improvement, increased the dose to 600 mg q12h and then to 800 mg q8h. At the latter dose, they found a spot CSF level of 2.6 mg/L; this level is in keeping with our results, as we found CSF levels just under 1 mg/L with 400 mg of iv ciprofloxacin q8h. Reports elsewhere of CSF penetration of ciprofloxacin have demonstrated less penetration with noninflamed meninges [4, 10, 12] . The persistence of significant CSF ciprofloxacin levels 1 week into ciprofloxacin treatment is difficult to fully explain, since the patient's condition had clinically improved. Either the blood-brain barrier was still abnormal (as suggested by the persistent inflammatory characteristics of CSF) or the dynamics of CSF ciprofloxacin penetration and elimination were altered. Because we were able to obtain only one late sample of CSF, we are unable to resolve this dilemma.
The relative constancy of the CSF levels suggests a slow flux of ciprofloxacin across the blood-brain barrier. Although we used 1200 mg/d in 3 divided doses to achieve these levels, there is a possibility that a similar outcome could be obtained by such frequent initial doses followed by more conventional twice daily dosing.
In conclusion, we have demonstrated that high doses of intravenous ciprofloxacin (400 mg q8h) produce and maintain CSF levels of almost 1 mg/L. Although no peak levels of ciprofloxacin were detected, the constant level that this regimen produces in CSF results in a prolonged time when the concentration is greater than the MIC. Because this dose resulted in no adverse effects and has previously been shown to be safe in patients with normal renal function, we recommend that 400 mg of intravenous ciprofloxacin q8h be considered for treatment of difficult-to-treat gram-negative bacillary meningitis.
